Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;126(12):907-912.
doi: 10.1111/apm.12902.

WHO laboratory validation of Xpert® CT/NG and Xpert® TV on the GeneXpert system verifies high performances

Affiliations

WHO laboratory validation of Xpert® CT/NG and Xpert® TV on the GeneXpert system verifies high performances

Susanne Jacobsson et al. APMIS. 2018 Dec.

Abstract

Effective tests for diagnosis of sexually transmitted infections (STIs), used point of care to inform treatment and management decisions, are urgently needed. We evaluated the analytical sensitivity and specificity of the Xpert® CT/NG and Xpert® TV tests, examining 339 samples spiked with phenotypically and/or genetically diverse strains of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis, and other related species that may cross-react. The APTIMA Combo 2 test and APTIMA TV test were used as reference tests. The analytical sensitivity for all three agents in the Xpert® CT/NG and Xpert® TV tests was ≤102 genome equivalents/reaction. The analytical specificity of both tests was high. False-positive results were identified in the Xpert® TV test when challenging with high concentrations of Trichomonas tenax, Trichomonas gallinae, Trichomonas stableri, and Trichomonas aotus. However, the clinical relevance of these cross-reactions can likely be neglected, because these species have not been identified in urogenital samples from humans. In conclusion, the analytical sensitivity and specificity of the user-friendly Xpert® CT/NG and Xpert® TV tests on the GeneXpert system were high. The results support the use of specimens from also extra-genital sites, for example, pharynx and rectum. However, appropriate clinical validations are additionally required.

Keywords: Chlamydia trachomatis; Neisseria gonorrhoeae; Trichomonas vaginalis; GeneXpert; Xpert® CT/NG; Xpert® TV; point of care.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS ONE 2015;10:e0143304. - PMC - PubMed
    1. Hobbs MM, Sefia AC. Modern diagnosis of Trichomonas vaginalis infection. Sex Transm Infect 2013;89:434–8. - PMC - PubMed
    1. Unemo M, Ballard R, Ison C. World Health Organization In: Unemo M, Ballard R, Ison C, editors. Laboratory Diagnosis of Sexually Transmitted Infections, Including Human Immunodeficiency Virus. Geneva, Switzerland: WHO, 2013.
    1. Peeling RW, Holmes KK, Mabey D, Ronald A. Rapid tests for sexually transmitted infections (STIs): the way forward. Sex Transm Infect 2006;82(Suppl 5):1–6. - PMC - PubMed
    1. Guy RJ, Causer LM, Klausner JD, Unemo M, Toskin I, Azzini AM, et al. Performance and operational characteristics of point‐of‐care tests for the diagnosis of urogenital gonococcal infections. Sex Transm Infect 2017;93(Suppl 4):16–21. - PubMed

Publication types